Clinical trial
Nivolumab as add-on to Gemcitabine/S-1 in Metastatic Pancreatic Cancer: a Phase II Trial
NCT04377048 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Nivolumab as add-on to Gemcitabine/S-1 in Metastatic Pancreatic Cancer: a Phase II Trial
- Lead sponsor
- National Taiwan University Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 1, 2020
- Completion date
- December 31, 2022
- Enrollment
- 38 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
stage iv pancreatic cancer